531015 — Venmax Drugs and Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- IN₹131.18m
- IN₹106.85m
- IN₹8.07m
Annual income statement for Venmax Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.68 | 0 | 0 | 0 | 8.07 |
| Cost of Revenue | |||||
| Gross Profit | -1.26 | 0 | 0 | 0 | 0.127 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.11 | 1.36 | 1.94 | 1.12 | 18.7 |
| Operating Profit | -3.43 | -1.36 | -1.94 | -1.12 | -10.7 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.62 | 18.5 | 2.26 | 0.869 | -0.141 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.62 | 18.5 | 2.26 | 0.645 | -0.105 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.62 | 18.5 | 2.26 | 0.645 | -0.105 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.62 | 18.5 | 2.26 | 0.645 | -0.105 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.31 | 3.52 | 0.43 | 0.12 | -0.02 |